Recombinant CD40L Treatment Protects Allogeneic Murine Bone Marrow Transplant Recipients From Death Caused by Herpes Simplex Virus-1 Infection

By Janice L. Beland, Heiko Adler, Nadia C. Del-Pan, Wende Kozlow, Janice Sung, William Fanslow, and Ilonna J. Rimm

Posttransplant infection associated with host immune deficiency is the major cause of nonrelapse mortality of human bone marrow transplant recipients. In a new murine model of posttransplant infection, allogeneic bone marrow transplant recipients were infected with herpes simplex virus-1 (HSV-1) via intraperitoneal inoculation 12 weeks after transplantation. Allogeneic transplant recipients with graft-versus-host disease (GVHD) had significantly increased mortality from HSV-1 encephalitis, with deficiencies of both specific anti-HSV-1 antibody and total serum IgG2a. GVHD mice displayed a Th2 cytokine profile (increased interleukin-4 [IL-4] and decreased interferon-γ) and decreased lipopolysaccharide (LPS) responses, suggesting that both T-cell and B-cell defects contributed to the impaired production of antibody. Because passive transfer of hyperimmune serum protected mice from HSV-1 infection, we hypothesized that CD40 ligand (CD40L), which induces B-cell maturation, would protect mice from HSV-1 infection. CD40L-treated GVHD mice showed elevated IgG2a levels and increased survival compared with vehicle-treated transplant recipients.

INFECTION ASSOCIATED with posttransplant immunodeficiency is the major cause of nonrelapse death in bone marrow transplant recipients. Posttransplant patients have frequent bacterial, viral, and fungal infections, indicating that infection is the result of host immunodeficiency rather than the virulent nature of a single pathogen. Defects in both B-cell and T-cell function contribute to human posttransplant immunodeficiency. Murine posttransplant immunodeficiency is associated with multiple functional defects, including impairments in T cells, B cells, adhesion molecules, and signaling molecules. Previous studies of viral infection with concurrent murine allogeneic bone marrow transplantation showed that infection and GVHD synergized to exacerbate the infection and increase graft-versus-host disease (GVHD). Earlier work has focused on viral infection that occurred concurrently with transplantation, before engraftment. However, many severe clinical infections occur after engraftment, and murine models have not yet been developed to address the issue of late infection.

We designed a murine model consisting of allogeneic bone marrow transplantation followed by herpes simplex virus-1 (HSV-1) infection to investigate the mechanisms of posttransplant immunodeficiency and to test potential cytokine therapies. HSV-1, which produces a rapid, measurable immune response, was chosen as a model pathogen to represent the herpes viruses which often infect bone marrow transplant patients. The goal of this work was to evaluate the effect of the posttransplant immunodeficient state on the response to a single, representative pathogen and to test potential cytokine therapies that may decrease morbidity and mortality due to viral infection.

Because CD40L treatment accelerated B-cell maturation in a syngeneic murine bone marrow transplant system, we have investigated the use of this cytokine as a therapy for posttransplant immunodeficiency. The binding of CD40L to CD40 stimulates B-cell proliferation, differentiation, and antibody secretion. Other effects of CD40L binding include B7-2 upregulation and the rescue of B cells from apoptosis.

MATERIALS AND METHODS

Mice. Female CBA/J and B10.BR mice, purchased from the Jackson Laboratory (Bar Harbor, ME), were transplanted at 11 to 13 weeks of age. The CBA/J and B10.BR mouse strains, which are both H-2k, differ at multiple minor histocompatibility loci. Transplantation of bone marrow from B10.BR mice to CBA/J mice simulated bone marrow transplantation with matched unrelated donors. Female Igh-6 (B-cell-deficient mice) were purchased from Jackson Laboratory and used at 12 weeks of age.

Bone marrow transplantation. Bone marrow was flushed from the femurs and tibiae of donor mice and washed one time with supplemented RPMI (RPMI1640 [Mediatech, Herndon, VA] with penicillin-streptomycin [100 IU/mL], L-glutamine [2 mM/L], 2-ME [55 μmol/L], HEPES [10 mM/L], and 10% heat-inactivated fetal bovine serum [Sigma, St Louis, MO]). Bone marrow cells were resuspended in Leibovitz’s L-15 medium (Life Technologies, Inc, Grand Island, NY).

Recipient mice were irradiated with 1,100 cGy split dose irradiation and then injected intravenously with donor bone marrow cells (5 × 10^6 cells). T-cell-depleted bone marrow transplant recipients were reconstituted with bone marrow that had been treated with two rounds of lysis with anti-Thy 1.2 and Complement (Accurate Chemicals & Scientific Corp, Westbury, NY). In one group, T cells (4 × 10^5 nylon wool passed spleen cells, 75% CD3+ cells) were added to the bone marrow to produce recipient mice, which developed minimal GVHD. All procedures were performed in accordance with protocols approved by the Animal Care Committee of the Dana-Farber Cancer Institute.

Viral infection with HSV-1 (KOS 1.1). The mice were infected with HSV-1 at 5 × 10^7 plaque forming units (pfu)/mouse via intraperitoneal injection 12 weeks after bone marrow transplantation. As in other studies of murine HSV-1 infection, examination of the central nervous system (CNS) tissues of dying GVHD mice showed the presence of HSV-1 antigen and inflammation (data not shown), suggesting HSV-1 encephalitis as the cause of death. Most deaths from HSV-1 infection occurred within 10 days of viral inoculation. Immunological studies below were performed on surviving mice.
CD40L treatment. Trimeric murine recombinant CD40L, was generously provided by Immunex (Seattle, WA). Mice were treated with 6 µg CD40L or vehicle (10% glycerol in saline) by intraperitoneal injection three times per week, starting the day before HSV-1 injection.

Cell culture preparation and proliferation assays. Two weeks after HSV-1 inoculation, mice were killed by CO2 asphyxiation and immunological studies were performed. Isolated splenocytes were washed and resuspended in supplemented RPMI. Viable cells were determined by Trypan blue exclusion.

Proliferation of recipient splenocytes to ultraviolet inactivated virus (4 × 106 pfu) or extract (a virus-free lysate of control Vero cells) was measured after 4 days incubation at 37°C and 5% CO2. Lipopolysaccharide (LPS, 10 µg/mL, Sigma)-stimulated proliferation was measured after 2 days. Recipient splenocytes were incubated in supplemented RPMI with LPS, inactivated virus, or extract in triplicate wells of 96-well microtiter plates with 4 × 106 cells/well. Cells were pulsed with 1 µCi 3H-thymidine/well for the final 5 hours of incubation and harvested. Incorporated 3H-thymidine was determined.

Flow cytometry. Splenocytes were stained for flow cytometry. FC receptor binding was blocked with phosphate-buffered saline (PBS) containing 10% rat whole serum (Zymed Laboratories, San Francisco, CA). As described, the following monoclonal antibodies, conjugated with either fluorescein isothiocyanate, phycoerythrin, or biotin (used with Streptavidin-Red670 [Life Technologies, Inc]) were used for staining: anti-B220, anti-CD4, anti-CD8, anti-CD3.

Specific anti-HSV-1 antibody and total serum IgG1 and IgG2a measurement. HSV-1-specific IgG1 and IgG2a antibodies in serum were determined by enzyme-linked immunosorbent assay (ELISA). Total serum IgG1 and IgG2a levels were determined using Radial Immunodiffusion (RID) Kits for mouse IgG1 and IgG2a (The Binding Site, Birmingham, UK). The tests were performed following the instructions of the manufacturer.

Cytokine detection. Splenocytes from immunized recipients were cultured with inactivated virus and supernatants collected. Interferon-γ (IFN-γ) and interleukin-5 (IL-5) levels were determined by ELISA. All measurements were performed using recombinant cytokine standards and "pairs" of capture and peroxidase-conjugated secondary antibodies, all purchased from PharMingen (San Diego, CA) and used according to the protocol supplied by PharMingen. The plates were developed using avidin-peroxidase and 3,3′-Azino-bis (3-ethylbenzthiazoline-6-sulfonic acid) (ABTS) substrate (Sigma) and read at 405 nm using an ELISA reader. The lower detection limit of the assay was 100 pg/mL for IFN-γ. To measure IL-4, culture supernatants were tested in collaboration with Dr Abul Abbas using the cytokine-dependent cell line CT4S in the presence of IL-2 blocking antibodies.

Passive transfer experiments. Hyperimmune HSV-1 antiseraum was generated in normal B10.BR mice by three intraperitoneal injections of HSV-1 (5 × 107 pfu/mouse) given at 2-week intervals. Serum was heat inactivated for 30 minutes at 56°C, and each mouse received 200 µL via tail vein injection.

Cytotoxic T lymphocyte (CTL) assay. Two weeks after viral infection, mice were killed and splenocyte cell suspensions (6 × 107 mononuclear cells) were prepared in 900 µL of unsupplemented RPMI. Cells were exposed to HSV-1 (ultraviolet irradiation-inactivated preparation equivalent to multiplicity of infection [MOI] of 1.5) in a total volume of 1.8 mL for 1 hour at 37°C. Supplemented RPMI 1640 (10 mL) was added and cultures were incubated for 4 days. Target L929 cells (American Type Culture Collection, Rockville, MD) were labeled overnight with 100 µCi 51Cr per 5 × 106 cells. On the day of assay, targets were incubated for 1 hour with HSV-1 (MOI = 10), washed and added at 1 × 106 cell/well to 96-well plates with effector cells at ratios of 100:1 to 3:1.2:1. Plates were incubated for 4 hours at 37°C and 5% CO2, centrifuged, and percent-specific lysis calculated.

Table 1. GVHD Mice Were More Susceptible to Lethal HSV-1 Infection

<table>
<thead>
<tr>
<th>Mouse Group</th>
<th>LD50‡</th>
</tr>
</thead>
<tbody>
<tr>
<td>GVHD</td>
<td>6.45 × 10^9 ‡</td>
</tr>
<tr>
<td>Control</td>
<td>1.63 × 10^9 ‡</td>
</tr>
<tr>
<td>B10 BR</td>
<td>4.08 × 10^9</td>
</tr>
<tr>
<td>CBA/J</td>
<td>2.45 × 10^9</td>
</tr>
</tbody>
</table>

*All results are the mean ± SEM of 8 to 20 mice per group. This experiment is representative of three similar experiments. **Significantly different, P < .001 by logistic regression analysis.

Results

GVHD mice have increased susceptibility to HSV-1. Irradiated CBA mice were reconstituted with T-cell-depleted bone marrow, or T-cell–supplemented bone marrow to generate an allogeneic control group (control) and a group with partial recovery from acute GVHD (GVHD). At 12 weeks posttransplantation, the GVHD group had a 20% weight loss due to GVHD as compared with the control group (Fig 1). In addition, the LD50 of control mice was more than twofold higher than that of GVHD mice (Table 1). Normal B10.BR and CBA/J mice had LD50 values greater than both transplant groups.

HSV-1 immune responses of GVHD mice. Twelve weeks after bone marrow transplantation, mice were infected with HSV-1 at a dose (5 × 106 pfu/mouse) chosen to ensure that sufficient numbers of GVHD mice survived for the analysis of the immune response. Two weeks after infection, HSV-1–specific T-cell proliferative (Fig 2A) and cytotoxic responses (Fig 2B) were equivalent in GVHD and control mice. Cells from GVHD mice produced decreased IFN-γ and increased IL-4 in response to HSV-1 (Fig 2C and D), consistent with a Th2 shift.

GVHD mice had impaired B-cell function, as measured by decreased proliferative response to LPS when compared with control mice (Fig 3A). Two weeks after HSV-1 infection, control mice generated a fivefold increase in total serum IgG2a.
Fig 2. T cells from GVHD mice generate normal proliferative and normal CTL response to HSV-1. GVHD mice display a Th2 cytokine response to HSV-1. (A) Nylon wool–separated T cells from GVHD mice respond well to HSV-1. 3H-Thymidine incorporation by recipient splenocytes in response to inactivated virus or media alone was measured. Groups consisted of two or three mice, and the mean and SEM are shown. This experiment is representative of three similar experiments. (B) HSV-1 CTL assays showed that GVHD and control mice generated similar CTL responses after HSV-1 infection. Lysis of mock-infected L929 targets was less than 20%. The data shown were from one of three similar experiments. (C) Splenocytes were cultured in vitro with ultraviolet irradiation-inactivated HSV-1 or with an extract from uninfected Vero cells, and IFN-γ production was measured from supernatants. The mean and standard error of three replicate wells are shown; data are representative of three similar experiments with three mice per group in each experiment. The quantity of IFN-γ produced by the extract control was below the limit of detection of the assay. Significant differences were detected between the extract and virus data (P ≤ .05, Student’s t-test). (D) Splenocytes were cultured in vitro with ultraviolet irradiation-inactivated HSV-1 or with an extract from uninfected Vero cells, and IL-4 production was measured from supernatants. Data from a single experiment is shown. Significant differences were detected between the extract and virus data (P ≤ .05, t-test). Results from two additional experiments measuring IL-5 were similar to the IL-4 experiment (data not shown).

(Fig 3B), a particularly important immunoglobulin subclass for immunity to viral infection. In contrast, GVHD mice failed to generate any increase in total serum IgG2a in response to HSV-1 (Fig 3B). In response to HSV-1 inoculation, control transplant recipients generated substantial levels of specific anti–HSV-1 IgG2a. However, the anti–HSV-1 IgG2a level of GVHD mice was only 25% of the control (Fig 3C). Total serum IgG1 and specific anti–HSV-1 IgG1 levels of GVHD mice were similar to control mice (data not shown). Because Th2 cytokines were critical for the production of IgG1, the decreased IgG2a production of GVHD mice was consistent with the finding that the cells from GVHD mice were polarized to a Th2 phenotype, as described in chronic GVHD.

Passive transfer of HSV-1 immune serum protected GVHD mice from HSV-1 mortality. Because B cells and antibody protected against HSV-1–induced mortality, we tested the hypothesis that antibody production was critical for successful immune response to HSV-1 infection. GVHD mice were given intravenous injection of either hyperimmune HSV-1 antisera or saline on the day after inoculation with 2 × 10⁶ pfu HSV-1. Hyperimmune HSV-1 antisera increased the survival of HSV-1 infected GVHD mice (Fig 4).

CD40L therapy prolonged survival and increased total serum IgG2a. To stimulate B-cell differentiation, 12-week-posttransplant recipients were treated with CD40L (6 µg) three times per week for 2 weeks until they were killed. Vehicle-treated mice
received a similar treatment with 10% glycerol. HSV-1 inoculation followed the first CD40L injection (schema shown on x-axis of Fig 5C).

Total serum immunoglobulin and specific anti–HSV-1 antibody of GVHD mice were measured before and after treatment.

CD40L-treated GVHD mice had improved survival compared with glycerol-treated GVHD mice (Fig 5C). These data suggest that CD40L therapy, which generates increased antibody production, protected HSV-1–infected GVHD mice from death.

To determine if CD40L effects on B cells were of primary importance, we tested if CD40L treatment could protect Igh-6 (B-cell–deficient mice)16 from HSV-1 infectious death. Two groups of B-cell–deficient mice were inoculated with CD40L or glycerol (6 µg intraperitoneally 3 × 3/wk). Both groups had similar mortality and all mice were dead by 9 days (Fig 5D). These data suggested that CD40L-mediated stimulation of B cells (rather than macrophages or CTL) was critical for HSV-1 infectious resistance.

Fig 4. Passive transfer of HSV-1 immune serum protected GVHD mice from HSV-1 mortality. GVHD mice were injected with hyperimmune HSV-1 serum or saline on the day following HSV-1 inoculation (2 × 10⁸ pfu). Survival was monitored daily. Survival of the two groups was significantly different (Wilcoxon rank sum test, \( P = .03 \)).

CD40L PROTECTS BMT RECIPIENTS FROM HSV-1 4475
Fig 5. CD40L treatment stimulated IgG2a production and improved survival of GVHD mice following HSV-1 infection but did not affect survival of B-cell–deficient mice. CD40L was given intraperitoneally (6 μg/mouse, three times a week) to control and GVHD mice. Vehicle-treated control and GVHD mice received glycerol diluted with saline. (A) Mice were inoculated with HSV-1 2 weeks before sacrifice. Serum was obtained by orbital bleed on day 14 immediately before killing. Total serum IgG2a was measured by radial immunodiffusion: (○) pre–HSV-1 infection, (□) post–HSV-1 glycerol-treated, (●) post–HSV-1 CD40L-treated. Significant differences (P < .05, t-test) were found between the glycerol and CD40L-treated GVHD groups. (B) Serum levels of HSV-1-specific and IgG2a were determined by ELISA 2 weeks post–HSV-1 infection: (○) post–HSV-1 glycerol-treated, (●) post–HSV-1 CD40L-treated. The increase in HSV-1–specific IgG2a in GVHD mice does not reach statistical significance. The data shown are the mean and SEM of six similar experiments that included 50 mice. (C) Mice were monitored daily for survival after infection with HSV-1. The GVHD-CD40L and GVHD-glycerol group are significantly different (P < .05, log-rank test). Each group included 15 mice. (D) Two groups of Igh-6 (B-cell–deficient) mice were inoculated with HSV-1 (1 × 10⁷ pfu, 4.5LD₅₀) and treated with: (○) CD40L or (●) glycerol. Both groups of mice have similar survival. The CD40L and glycerol groups each included three mice.
DISCUSSION

To establish an animal model of posttransplant infection related morbidity and mortality, we inoculated murine allogeneic bone marrow transplant recipients with HSV-1 after engraftment. Allogeneic transplant recipients with GVHD had increased mortality from HSV-1 and generated decreased total serum IgG2a and decreased specific anti–HSV-1 antibody in response to HSV-1 infection. Passive transfer of immunoglobulin protected GVHD mice and B-cell–deficient mice from HSV-1 encephalitis, suggesting that B cells and immunoglobulin were of primary importance in protection from HSV-1 encephalitis.

Because CD40L promoted B-cell maturation in a syngeneic bone marrow transplant model, we tested the ability of CD40L to improve survival of allogeneic transplant recipients after HSV-1 infection. When given concurrently with HSV-1, CD40L therapy increased the level of total serum IgG2a and improved the survival of allogeneic mice with GVHD.

The concurrence of GVHD and viral infection exacerbated the pathology of both diseases. Using the Parent into F1 (P → F1) model of graft-versus-host reaction (GVHR), Shanley and colleagues found that mice with concurrent murine cytomegalovirus (MCMV) infection and GVHR developed a severe interstitial pneumonitis that was not detected in mice with either MCMV or GVHD alone. Cray and Levy, using the P → F1 model, detected increased anti-host CTL activity in MCMV-infected animals. Antihost CTL activity was a measure of increased GVHD during infection. In both of these studies viral infection and GVHR were induced simultaneously. Increased host immunodeficiency was reported by Via et al. in infection and GVHR were induced simultaneously. Increased GVHD during infection. In both of these studies viral infection and GVHR were induced simultaneously. Increased host immunodeficiency and increased morbidity and mortality due to viral infection.

Alternative mechanisms may have contributed to CD40L-induced protection from HSV-1 mortality. CD40L may have caused B7-2 upregulation, which increased both CTL generation and/or macrophage IL-12 production. Either augmented HSV-1 CTL activity or IL-12 action could have produced HSV-1 protection. Data showing that CD40L failed to protect B-cell–deficient mice from HSV-1 infection (Fig 5D) make these explanations less likely.

Although anti-CD40L antibody treatment early after transplantation limited the development of GVHD, 34-35 we did not observe any increase in GVHD in CD40L-treated mice; this may be due to the timing of our CD40L treatments. At 12 weeks after transplantation, the initial critical expansion of mature donor T cells had already occurred. Therefore, late CD40L treatment may avoid stimulation of mature donor T-cell expansion, while allowing the enhancement of newly developed immune responses.

In our new model of posttransplant immunodeficiency, HSV-1 infection of murine transplant recipients with GVHD resulted in decreased antibody production and increased mortality. CD40L therapy increased total serum IgG2a production and improved survival after HSV-1 infection, suggesting that B-cell maturation stimuli may improve posttransplant immunodeficiency.

ACKNOWLEDGMENT

The authors thank Dr Steven Burakoff for helpful conversations and Dr Paul Martin for critical reading of the manuscript.

REFERENCES

22. McKnight AJ, Shea CM, Wiens GR, Rimm IJ, Abbas AK: Differentiation of Vα8.2+ CD4+ T cells induced by a superantigen: Roles of antigen-presenting cells and cytokines. Immunology 81:513, 1994
Recombinant CD40L Treatment Protects Allogeneic Murine Bone Marrow Transplant Recipients From Death Caused by Herpes Simplex Virus-1 Infection

Janice L. Beland, Heiko Adler, Nadia C. Del-Pan, Wende Kozlow, Janice Sung, William Fanslow and Ilonna J. Rimm